Pfizer (PFE) Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
Go back to Pfizer (PFE) Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age| Pfizer Inc. (NYSE: PFE) | Delayed: 24.99 -0.22 (0.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.21 | 52 Week High | $37.39 | |||
| Open | $25.22 | 52 Week Low | $28.25 | |||
| Day High | $25.31 | P/E | 15.15 | |||
| Day Low | $24.96 | EPS | $1.65 | |||
| Volume | 28,441,962 | |||||
